These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17288910)

  • 21. Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
    Pham PA
    Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical trials for enfuvirtide (Fuzeon, T-20).
    Crabb C
    AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
    [No Abstract]   [Full Text] [Related]  

  • 23. Enfurvirtide safety in human immunodeficiency virus-infected children.
    Baylor MS; Johann-Liang R
    Pediatr Infect Dis J; 2005 Apr; 24(4):389-90. PubMed ID: 15818309
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.
    Wiznia A; Church J; Emmanuel P; Eppes S; Rowell L; Evans C; Bertasso A;
    Pediatr Infect Dis J; 2007 Sep; 26(9):799-805. PubMed ID: 17721374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment with a new fusion inhibitor: patient issues with enfuvirtide (T-20). A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.
    Glutzer E
    AIDS Read; 2003 Mar; 13(3 Suppl):S14-6. PubMed ID: 12765161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1-infected man.
    DeSimone JA; Ojha A; Pathak R; Cohn J
    Clin Infect Dis; 2004 Nov; 39(10):e110-2. PubMed ID: 15546072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1].
    Raffi F
    Med Mal Infect; 2004 Sep; 34 Spec No 1():8-17. PubMed ID: 15742550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reassessment of enfuvirtide's role in the management of HIV-1 infection.
    Marr P; Walmsley S
    Expert Opin Pharmacother; 2008 Sep; 9(13):2349-62. PubMed ID: 18710359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enfuvirtide.
    Dando TM; Perry CM
    Drugs; 2003; 63(24):2755-66; discussion 2767-8. PubMed ID: 14664654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort.
    Talbot A; Machouf N; Thomas R; Marcotte S; Therrien R; Lessard B; Dufresne S; Lalonde R
    J Acquir Immune Defic Syndr; 2009 Jul; 51(3):362-4. PubMed ID: 19553775
    [No Abstract]   [Full Text] [Related]  

  • 31. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
    Cervia JS; Smith MA
    Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide.
    Beatty G; Hunt P; Smith A; Hoh R; Huang W; Martin J; Deeks SG
    Antivir Ther; 2006; 11(3):315-9. PubMed ID: 16759047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enfuvirtide and cutaneous injection-site reactions.
    Mirza RA; Turiansky GW
    J Drugs Dermatol; 2012 Oct; 11(10):e35-8. PubMed ID: 23134996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA notifications. Enfuvirtide has new instructions.
    AIDS Alert; 2007 Apr; 22(4):44-5. PubMed ID: 17595723
    [No Abstract]   [Full Text] [Related]  

  • 36. Virologic and immunologic impact and durability of enfuvirtide-based antiretroviral therapy in HIV-infected treatment-experienced patients in a clinical setting.
    Loutfy MR; Antoniou T; Shen S; Diong C; Vlaicu M; Halpenny R; Kovacs C; Fletcher D; Raboud JM
    HIV Clin Trials; 2007; 8(1):36-44. PubMed ID: 17434847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A delayed hypersensitivity reaction to enfuvirtide after rechallenge.
    Emerson CR; Post JJ; Workman C
    Int J STD AIDS; 2009 Apr; 20(4):288-9. PubMed ID: 19304981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.
    Edmunds-Ogbuokiri T
    HIV Clin; 2007; 19(1):1-3. PubMed ID: 17405221
    [No Abstract]   [Full Text] [Related]  

  • 39. Enfuvirtide nursing guidelines: a report from the Association of Nurses in AIDS Care Expert Panel on Enfuvirtide.
    Foy K; Bradley-Springer L; Kempner T; Stevens L; Gahagan L
    J Assoc Nurses AIDS Care; 2005; 16(2):2-12. PubMed ID: 16438121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enfuvirtide access, administration, and patient education.
    Celano SA
    Hopkins HIV Rep; 2003 May; 15(3):1, 12. PubMed ID: 12809102
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.